CN112638394A - Composition for preventing or treating prostate disease comprising Japanese stauntonvine extract and dogwood extract as active ingredients - Google Patents
Composition for preventing or treating prostate disease comprising Japanese stauntonvine extract and dogwood extract as active ingredients Download PDFInfo
- Publication number
- CN112638394A CN112638394A CN201980055052.XA CN201980055052A CN112638394A CN 112638394 A CN112638394 A CN 112638394A CN 201980055052 A CN201980055052 A CN 201980055052A CN 112638394 A CN112638394 A CN 112638394A
- Authority
- CN
- China
- Prior art keywords
- extract
- japanese
- preventing
- stauntonvine
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 166
- 208000017497 prostate disease Diseases 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000004480 active ingredient Substances 0.000 title claims abstract description 24
- 240000001490 Stauntonia hexaphylla Species 0.000 title claims description 62
- 240000006766 Cornus mas Species 0.000 title 1
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 31
- 241000209020 Cornus Species 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 206010060862 Prostate cancer Diseases 0.000 claims description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 15
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 14
- 240000000425 Chaenomeles speciosa Species 0.000 claims description 14
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims description 14
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 14
- 235000013402 health food Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 201000007094 prostatitis Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 abstract description 25
- 108010080146 androgen receptors Proteins 0.000 abstract description 20
- 102000001307 androgen receptors Human genes 0.000 abstract description 20
- 150000001875 compounds Chemical class 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 14
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 235000013502 Pyrus japonica Nutrition 0.000 abstract description 7
- 239000000427 antigen Substances 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 7
- 241001605888 Chaenomeles japonica Species 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 description 38
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 20
- 238000002156 mixing Methods 0.000 description 18
- 238000000605 extraction Methods 0.000 description 16
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 15
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 15
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 15
- 229960003604 testosterone Drugs 0.000 description 15
- 235000014570 Stauntonia hexaphylla Nutrition 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 244000184734 Pyrus japonica Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 229960003473 androstanolone Drugs 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- -1 patch Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000133425 Stauntonia Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 244000063616 Sabal blackburniana Species 0.000 description 2
- 241000340661 Stauntonia chinensis Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000004908 prostatic fluid Anatomy 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VMNRNUNYBVFVQI-RLWQEURSSA-N 3-oxo-5α-steroid Chemical compound C([C@@H]1CC2)C(=O)CCC1(C)C1C2C2CCCC2(C)CC1 VMNRNUNYBVFVQI-RLWQEURSSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- ACFIXJIJDZMPPO-NCHANQSKSA-N nadph Chemical compound C1=CCC(C(=O)N)=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2[C@@H]([C@H](OP(O)(O)=O)[C@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NCHANQSKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition for preventing or treating prostate diseases comprising extracts of chaenomeles japonicas and cornus officinalis as active ingredients, and more particularly, to a composition for preventing or treating prostate diseases, which comprises a compound extract of chaenomeles japonicas and cornus officinalis as an active ingredient, has no cytotoxicity, and has an excellent inhibitory effect on the expression of androgen receptors, prostate-specific antigens and prostate-specific enzymes, and thus can be used as an active ingredient of a composition for preventing or treating prostate diseases.
Description
Technical Field
The present invention relates to a composition for preventing or treating prostate diseases, which comprises an extract of Stauntonia hexaphylla and an extract of Cornus officinalis (Cornus officinalis sieb. et Zucc) as active ingredients.
Background
The prostate gland is an accessory gonad composed of glandular tissue and fibromuscular tissue, and plays a role in producing and secreting semen. The prostatic fluid produced in the prostate gland supplies nutrients to the sperm that are produced and move in the testis and helps the sperm to move actively by maintaining the fluid state so that the ejaculated semen does not coagulate. Typical prostate diseases include prostatic hyperplasia, prostate cancer and prostatitis.
Prostatic Hyperplasia (BPH) is one of the diseases commonly seen in adult men, and it is reported that the incidence rate of men over 50 years old is 50%, and that the incidence rate of men over eighty years old is 80% or more, and the frequency of occurrence in male urinary tract disorders is the highest. The number of patients with prostatic hyperplasia in korea has increased from 45 ten thousand to 9 thousand in 2006 to 84 ten thousand to 2 thousand in 2011, and has a growth rate of 83.5%, and recently, the incidence of the disease has sharply increased.
Generally, the size of the prostate of an adult is about 20g, and if the prostate is enlarged to an abnormal size and reaches 40 to 400g, the prostate presses the nearby urinary tract, and therefore, there are symptoms such as urinary bladder urine storage symptoms such as frequent urination 8 times or more a day, frequent urination at night, urinary urge in which urination is not suppressed because a strong and sudden urinary sensation is felt, urinary waiting for urination until urination is achieved by a urinary delay or a urinary interruption, and urinary bladder discharge disorders such as a need to apply force during urination. Prostate hyperplasia does not require surgical treatment without urinary occlusion or other complications, but about 50% of patients by age 80 still require treatment. Moreover, some of patients with prostatic hyperplasia are related to prostate cancer, and although this is not a fatal disease, it is becoming an important medical problem in the current society that is advancing to the super-aging society in terms of reducing the quality of life.
At the beginning, the treatment of prostatic hyperplasia was almost surgical, but the method of administration was rapidly changing from the second half of the last eighties. However, since the conventional drugs for treating prostatic hyperplasia have many side effects and limited efficacy, development of a novel therapeutic agent having no side effects, no drug resistance, and excellent therapeutic effect is required.
Prostate cancer is the most common cancer among male cancers in the west, and presents a very high incidence rate, which is also rapidly increasing in korea. The treatment of prostate cancer varies depending on the stage of disease, and in the case of local cancer, treatment is performed for radical treatment, but in the case of metastatic cancer, systemic treatment is required. The local prostate cancer may be selected from environmental therapy, radical prostatectomy, and radiation therapy in consideration of the age, health status, sexual function status, the change stage and differentiation degree of tumor, preference degree of patient, etc. Metastatic prostate cancer can be treated with hormone and anticancer therapy.
Prostatitis, a disease in which the prostate gland produces inflammation, is a very common disease in which about 50% of adult men experience the symptoms once in a lifetime. Urinary infection is often caused by direct infection of bacteria through the urinary tract, and may also be caused by disturbance of excretion of prostatic fluid, backflow of urine into the prostate, infection with inflammation such as hemorrhoid and colitis, and the like.
Since the above prostate diseases such as prostate cancer, prostatic hyperplasia and prostatitis are related to androgen which is a male hormone, therapeutic and prophylactic effects on diseases or symptomatic relief effects can be obtained by anti-androgen drugs which inhibit the expression of androgen receptors. In addition, a prostate-specific antigen inhibitor that inhibits the expression of a prostate-specific antigen is also effective for the prevention and treatment/symptom improvement of the above-mentioned prostate diseases that are affected by the prostate-specific antigen. Meanwhile, 5-alpha reductase inhibitors which inhibit androgen are also used for the treatment of male diseases caused by androgen, such as prostatic hyperplasia, alopecia, etc. More specifically, 5- α reductase, which converts testosterone (testosterone), which is a male hormone, into Dihydrotestosterone (DHT), is used as reduced coenzyme ii (nadph) -dependent 3-oxo 5 α -steroid dehydrogenase (3-oxo-5 α -steroid-dehydrogenase) of microsomes (microsomes) to reduce doubly bound steroids such as testosterone. The 5-alpha reductase has subtypes of type 1, type 2, and type 3, with type 1 being mainly present in several organs such as skin and liver tissue, and type 2 being mainly present in liver and genitourinary including prostate. In prostate tissue, more than 90% of testosterone is converted to dihydrotestosterone by 5-alpha reductase, and dihydrotestosterone promotes prostate growth with about 10 times more activity than testosterone. Therefore, if 5-alpha reductase is effectively inhibited, the synthesis of dihydrotestosterone, which has strong physiological activity, can be reduced, and finally prostatic hyperplasia can be improved or even treated. In addition, in the same way as in prostatic hyperplasia, when dihydrotestosterone is synthesized excessively by 5-alpha reductase, dihydrotestosterone binds to androgen receptors around hair follicles, gradually shrinking and degenerating the hair follicles, and thus causing alopecia. Thus, alopecia can be improved or even treated by effectively inhibiting 5-alpha reductase.
On the other hand, Stauntonia chinensis, which is a plant of evergreen vine of the family akebiaceae and is known as Stauntonia Hexaphylla, is found in streams or bushes in southern regions of korea, such as the whole south, kyo south, and loyalty south. The stem, leaf and root are used as medicinal materials and are known to have significant effects on resisting inflammation, relieving fever and pain. And may also be used as a cardiotonic agent to restore function to normal when the heart is weakened or incomplete, or as a diuretic agent to expel excess water from the body. In addition, it is known that it is effective for inhibiting subcutaneous fat accumulation, joint diseases, uterine fibroids, facial neuralgia, and the like.
Cornus officinalis (Corni Fructus) is a ripe, depeded pulp derived from Cornus officinalis Siebold et Zuccarini (Cornaceae). The bag-shaped plastic bag is irregular block-shaped or bag-shaped, and has a length of about 10-15 mm and a width of about 1 cm. The outer surface is dark red to dark purple, and the surface has moist and rough wrinkles. The pulp has the trace of removing seeds, the upper part has the trace of calyx, and the lower part has the trace of fruit stem. It has soft meat quality, slight smell, and sour and sweet taste. It is known that cornus officinalis has diuretic, antihypertensive, tonic, antiallergic, antihistaminic, anticholinergic, antipbarium, antimicrobial (antifungal) and other effects.
Accordingly, the present inventors have made an effort to develop a therapeutic agent for prostate diseases derived from natural products, which ensures safety and has no side effects, and have confirmed that a complex extract of chaenomeles speciosa and cornus officinalis has no cytotoxicity and an excellent inhibitory effect on the expression of androgen receptors, prostate-specific antigens and prostate-specific enzymes, and have found that the compound extract can be used as an active ingredient of a composition for preventing or treating prostate diseases, thereby completing the present invention.
Disclosure of Invention
Technical problem to be solved by the invention
The present invention is directed to a pharmaceutical composition for preventing or treating prostate diseases, comprising extracts of Japanese stauntonvine and Cornus officinalis as active ingredients.
It is still another object of the present invention to provide a method for preventing or treating a prostate disease, which comprises the step of administering pharmaceutically effective amounts of the extracts of chaenomeles japonicas and cornus officinalis to an individual.
Another object of the present invention is to provide a use of the japanese stauntonvine extract and the dogwood extract as a composition for preventing or treating prostate diseases.
Means for solving the problems
In order to achieve the above objects, the present invention provides a pharmaceutical composition for preventing or treating prostate diseases, comprising extracts of chaenomeles japonicas and cornus officinalis as effective ingredients.
Also, the present invention provides a health food for preventing or improving prostate diseases, which comprises the extract of chaenomeles speciosa and the extract of cornus officinalis as effective ingredients.
Also, the present invention provides a food composition for preventing or improving prostate diseases, comprising the extract of chaenomeles speciosa and the extract of cornus officinalis as active ingredients.
Also, the present invention provides a method for treating prostate diseases, which comprises the step of administering pharmaceutically effective amounts of the extracts of chaenomeles japonicas and cornus officinalis to an individual.
Also, the present invention provides a method for preventing or ameliorating a prostate disease, comprising the step of administering a pharmaceutically effective amount of the extracts of Japanese stauntonvine and Corni fructus to an individual.
Also, the present invention provides a use of the Japanese stauntonvine extract and the Cornus officinalis extract as a pharmaceutical composition for preventing or treating prostate diseases.
Also, the present invention provides a use of the Japanese stauntonvine extract and the Cornus officinalis extract as a health food for preventing or improving prostate diseases.
Meanwhile, the present invention provides a use of the Japanese stauntonvine extract and the dogwood extract as a food composition for preventing or improving prostate diseases.
ADVANTAGEOUS EFFECTS OF INVENTION
The compound extract of chaenomeles speciosa and dogwood of the present invention has no cytotoxicity, has excellent inhibitory effects on the expression of androgen receptors, prostate specific antigens and prostate specific enzymes, and can be used as an active ingredient of a composition for preventing or treating prostate diseases.
Drawings
FIG. 1 is a graph showing the confirmation of cytotoxicity after treating human prostate cancer (LNCaP) cells with the Japanese stauntonia extract, the Corni fructus extract or the Japanese stauntonia and Corni fructus complex extract prepared in the examples of the present invention at concentrations of 0. mu.g/ml, 10. mu.g/ml, 25. mu.g/ml and 50. mu.g/ml, respectively.
FIG. 2 is a graph showing the confirmation of the change in the expression of Androgen Receptor (AR), Prostate Specific Antigen (PSA) and 5-alpha reductase (5 alpha-reductase) 2 proteins after treating human prostate cancer cells with 1. mu.M testosterone in combination with 25. mu.g/ml, 50. mu.g/ml concentration of Japanese stauntonvine extract, 50. mu.g/ml concentration of Corni fructus extract or 25. mu.g/ml concentration of Japanese stauntonvine and Corni fructus complex extract prepared in the present examples.
Detailed Description
The present invention will be described in more detail below.
The present invention provides a pharmaceutical composition for preventing or treating prostate diseases comprising Japanese stauntonvine extract and dogwood extract as active ingredients.
Also, the present invention provides a use of the Japanese stauntonvine extract and the Cornus officinalis extract as a pharmaceutical composition for preventing or treating prostate diseases.
Preferably, the japanese stauntonvine extract and the dogwood extract, which are the effective ingredients of the present invention, are prepared by a method comprising the following steps, respectively, but not limited thereto:
step 1), adding an extraction solvent to the Japanese stauntonvine and the dogwood respectively for extraction;
step 2), filtering the extract of step 1);
step 3), concentrating the filtrate obtained in the step 2) under reduced pressure;
and step 4) drying the concentrate of step 3).
In the preparation method of the present invention, the Japanese stauntonvine or the dogwood of the step 1) can be used without limitation, whether cultivated or marketed. Also, the above Japanese stauntonia may be flower, branch, stem, leaf, fruit, aerial part, rhizome, root or combination thereof of Japanese stauntonia, more specifically, Japanese stauntonia leaf.
In the preparation method of the present invention, preferably, the extraction solvent of the above step 1) may use water, alcohol or a mixture thereof. Preferably, the above alcohol is used C1To C2Preferably, a lower alcohol ofEthanol or methanol is used. Preferably, the extraction method uses shaking extraction, Soxhelt extraction, or reflux extraction, but is not limited thereto. Preferably, the extraction solvent is added in an amount of 1 to 20 times, more preferably 3 to 17 times, and still more preferably 5 to 15 times the amount of the dried Japanese stauntonvine or dogwood. Preferably, the extraction temperature is 10 to 100, but is not limited thereto. And, preferably, the extraction time is 1 to 72 hours, but is not limited thereto. Meanwhile, the number of extraction is preferably 1 to 5, more preferably 3 to 4, and further preferably 3, but not limited thereto.
In the preparation method of the present invention, preferably, the reduced pressure concentration of step 3) uses a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto. Also, preferably, the drying is reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
In the preparation method of the present invention, the extract of japanese stauntonvine and the extract of dogwood may be prepared by mixing the respective extracts after preparing the extracts, or may be prepared by mixing japanese stauntonvine and dogwood and obtaining their extracts after mixing them.
The above composition may contain the extract of Stauntonia japonica and the extract of Cornus officinalis at a weight ratio of 5: 5 to 9.5: 0.5, specifically 6: 4 to 9.5: 0.5, more specifically 7: 3 to 9.5: 0.5, further specifically 8: 2 to 9.5: 0.5, further specifically 8.5: 2.5 to 9.5: 0.5.
The prostate disease may be, for example, prostate cancer, prostatic hyperplasia or prostatitis.
In an embodiment of the present invention, the present inventors prepared a compound extract of japanese stauntonia chinensis and dogwood by mixing the above extracts in various mixing ratios after preparing a 70% alcohol extract of japanese stauntonia chinensis leaves and a 70% alcohol extract of dogwood.
The present inventors also confirmed the cytotoxicity of the above-mentioned compound extract of chaenomeles speciosa and dogwood in prostate cancer cells, and confirmed that the compound extract was not cytotoxic at various concentrations (see fig. 1).
The present inventors also confirmed that the complex extract has an excellent effect of inhibiting the expression of a protein of Androgen Receptor (AR), Prostate Specific Antigen (PSA), and prostate specific enzyme (5- α reductase 2) in prostate cancer cells treated with testosterone together with the complex extract of chaenomeles speciosa and dogwood (see fig. 2).
Accordingly, the present inventors confirmed that the complex extract of chaenomeles speciosa and dogwood of the present invention has no cytotoxicity and excellent inhibitory effects on the expression of androgen receptors, prostate-specific antigens and prostate-specific enzymes, and thus the complex extract of chaenomeles speciosa and dogwood of the present invention can be effectively used as an active ingredient of a pharmaceutical composition for preventing or treating prostate diseases or a pharmaceutical composition for preventing or ameliorating male diseases caused by testosterone, such as alopecia.
The compositions of the invention may be administered orally or non-orally (e.g. by spreading or intravenous, subcutaneous, intraperitoneal injection). The preparations for non-oral administration may be used in the form of external preparations such as powder, granule, tablet, capsule, sterile aqueous solution, liquid, non-aqueous solvent, suspension, emulsion, syrup, suppository, aerosol, etc. and sterile injection, respectively, according to the usual methods, and preferably, may be used in the form of pharmaceutical compositions for external use for skin prepared as cream, gel, patch, spray, ointment, plaster, emulsion, liniment, paste or gel ointment, but are not limited thereto. The compositions for topical administration may be anhydrous or aqueous, depending on the clinical prescription. As the nonaqueous solvent or suspending agent, propylene glycol (propylene glycol), polyethylene glycol, vegetable oil such as olive oil, or injectable ester such as ethyl oleate can be used. The base of suppository can be semisynthetic fatty acid ester (witepsol), polyethylene glycol, tween (tween)61, cacao butter, hydroxycitronellal, glycerogelatin, etc. Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills and the like. Liquid preparations for oral administration include suspensions, internal liquids, oils, syrups, aerosols and the like, and may contain excipients such as wetting agents, sweeteners, aromatics, preservatives and the like in addition to water and liquid paraffin, which are widely used as simple diluents.
For administration, the composition may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredient of the present invention. The pharmaceutically acceptable carrier may be physiological saline, sterilized water, ringer's solution, buffered physiological saline, glucose solution, maltodextrin solution, glycerol, ethanol, or a mixture thereof, and may further contain other common additives such as antioxidant, buffer, bacteriostatic agent, etc., as required. In addition, a diluent, a dispersant, a surfactant, a binder and a lubricant may be added to prepare an injection preparation such as an aqueous solution, a suspension, an emulsion and the like.
Preferably, the pharmaceutically acceptable additive of the present invention may be contained in an amount of 0.1 parts by weight to 90 parts by weight, relative to the above composition.
The preferred administration amount of the composition of the present invention varies depending on the degree of absorption of the active ingredient in the body, the age, sex and degree of obesity of the patient, and can be appropriately selected by one of ordinary skill in the art to which the present invention pertains. However, for preferable effects, in the case of oral administration dosage forms, it can be generally administered to an adult in an amount of 0.0001mg/kg to 500mg/kg per day, preferably 0.001mg/kg to 300mg/kg, more preferably 0.01mg/kg to 200 mg/kg. The administration can be carried out once a day or several times. The above dosage does not limit the scope of the present invention in any way.
Also, the present invention provides a health food for preventing or improving prostate diseases, which comprises the extract of chaenomeles speciosa and the extract of cornus officinalis as effective ingredients.
Also, the present invention provides a food composition for preventing or improving prostate diseases, comprising the extract of chaenomeles speciosa and the extract of cornus officinalis as active ingredients.
Also, the present invention provides a use of the Japanese stauntonvine extract and the Cornus officinalis extract as a health food for preventing or improving prostate diseases.
Also, the present invention provides a use of the Japanese stauntonvine extract and the Cornus officinalis extract as a food composition for preventing or improving prostate diseases.
The above-mentioned japanese stauntonvine extract and dogwood extract, their mixing ratio, and prostate disease are the same as those described above with respect to the pharmaceutical composition for preventing or treating prostate disease, and therefore the specific description refers to the above-mentioned contents, and only the specific structure of the health food or food composition will be described below.
On the other hand, it was confirmed that the complex extract of chaenomeles speciosa and dogwood of the present invention has no cytotoxicity and is excellent in the inhibitory effect on the expression of androgen receptor, prostate specific antigen and prostate specific enzyme, and thus the complex extract of the present invention can be effectively used as an active ingredient of health food or food composition for preventing or improving prostate disease. Also, the complex extract of the present invention can be effectively used as an active ingredient of a health food or food composition for preventing or improving male diseases caused by testosterone, such as alopecia.
The two extracts of the present invention may be provided as a health food or food composition in admixture with a dietetically acceptable carrier.
The health food of the invention comprises the forms of tablets, capsules, pills or liquid, etc.
When the two extracts of the present invention are used as additives for foods or drinks, the two extracts may be added as they are, or may be used together with other foods or food ingredients, and may be used as appropriate according to a common method. The mixing amount of the above two extracts may be appropriately determined depending on the purpose of use thereof (preventive, health or therapeutic treatment). In the case of long-term ingestion for the purpose of health and hygiene or for the purpose of health regulation, since both of the above extracts have no problem in terms of safety, they can be taken for a long period of time. The kind of the above-mentioned food is not particularly limited.
Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, sugar, snack, biscuit, pizza, stretched noodles, other noodles, chewing gum, milk products including ice cream, various soups, beverages, tea, drinkable preparation, alcoholic beverage, and vitamin complex. In the case of preparing a beverage, liquid components to be added in addition to the above two extracts are not limited, but a plurality of flavors, natural carbohydrates, and the like may be added as additional components as in the case of a normal beverage. Examples of the natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), polysaccharides (e.g., general sugars such as dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, erythritol. The proportion of natural carbohydrates is between 1g and 20g, preferably between 5g and 12g, per 100ml of the composition according to the invention. In addition to the above, natural flavors (thaumatin, stevia extracts (e.g., rebaudioside a, glycyrrhizic acid, etc.)) and synthetic flavors (e.g., saccharin, aspartame, etc.) can be used.
The food composition of the present invention may contain various nutrients, vitamins, flavors such as inorganic substances (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate and the like), pectic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents for carbonated beverages, and the like. Also, the food composition of the present invention may comprise pulp for preparing fruit and vegetable beverages. These ingredients may be used alone or in combination, and the proportion of these additives is generally selected in the range of 0.001 to 50 parts by weight relative to the total weight of the composition.
Also, the present invention provides a method for preventing or ameliorating a prostate disease, comprising the step of administering a pharmaceutically effective amount of the extracts of Japanese stauntonvine and Corni fructus to an individual.
Also, the present invention provides a method for treating prostate diseases, which comprises the step of administering pharmaceutically effective amounts of the extracts of Japanese stauntonvine and Corni fructus to an individual.
The above-mentioned Japanese stauntonvine extract and the extract of Cornus officinalis, the mixing ratio thereof, and the prostate disease are the same as those described above with respect to the pharmaceutical composition for preventing or treating prostate disease, and the specific description is incorporated above.
On the other hand, it was confirmed that the complex extract of chaenomeles speciosa and dogwood of the present invention has no cytotoxicity and an excellent inhibitory effect on the expression of androgen receptors, prostate specific antigens and prostate specific enzymes, and thus the complex extract of the present invention can be effectively used for the prevention, amelioration or treatment of prostate diseases. Also, the complex extract of the present invention can be effectively used for the prevention or improvement of male diseases caused by testosterone, such as alopecia.
The present invention will be described in detail below with reference to examples, experimental examples, and preparation examples.
However, the following examples, experimental examples and preparation examples merely illustrate the present invention, and the contents of the present invention are not limited to the following examples, experimental examples and preparation examples.
Example 1 preparation of Japanese Stauntonia extract
20g of dried Japanese stauntonia leaves were put in 300ml of 70% ethanol and subjected to low-temperature extraction by ultrasonic waves for 12 hours. After filtering the obtained extract using filter paper, the filtered residue was subjected to low-temperature extraction using 300ml of 70% alcohol for 12 hours and the filtering process was repeated two more times. After the extraction is finished, the filtrates are combined and the Japanese stauntonvine extract is obtained through the processes of decompression concentration and freeze drying.
Example 2 preparation of extract of Cornus officinalis
20g of dried Corni fructus was put in 300ml of 70% ethanol, and extracted at low temperature by ultrasonic wave for 12 hours. After filtering the obtained extract using filter paper, the filtered residue was subjected to low-temperature extraction using 300ml of 70% alcohol for 12 hours and the filtering process was repeated two more times. After extraction, combining the filtrates, and concentrating under reduced pressure and freeze drying to obtain Corni fructus extract.
Example 3 preparation of Compound extract of Japanese Stauntonia chinensis and Cornus officinalis
The compound extracts of japanese stauntonvine and dogwood were prepared by mixing the extract of japanese stauntonvine obtained in the above example 1 and the extract of dogwood obtained in the above example 2 at the mixing ratios shown in the following table 1.
TABLE 1
Experimental example 1 confirmation of cytotoxicity of Compound extract of Stauntonia japonica and Cornus officinalis
In order to observe the cytotoxicity of the compound extract of stauntonia japonica and dogwood, the cell survival rate was confirmed after prostate cancer cells were treated with the compound extract of stauntonia japonica and dogwood.
Specifically, LNCaP cells (ATCC company, USA) as a male hormone-dependent human prostate cancer cell line were cultured in RPMI-1640 medium (Gibco company) containing 10% Fetal Bovine Serum (FBS) at 37 ℃ and 5% CO2Culturing under the conditions of (1). The cultured cells were cultured in a 96-well plate at 1X 104The concentration of cells (cells)/well (well) was measured, and the cells were cultured under the same conditions as described above for 18 hours. Then, the Japanese stauntonvine extract prepared in the above example 1, the Corni fructus extract prepared in the above example 2, or the Japanese stauntonvine and Corni fructus complex extract prepared in the above example 3 were treated with concentrations of 0. mu.g/ml, 10. mu.g/ml, 25. mu.g/ml, and 50. mu.g/ml, respectively, and cultured for 72 hours, and then a cell viability assay kit (EX-cytox model, Daei Lab Service, Korea) solution was added according to the manufacturer's procedure, and absorbance was measured at 450nm using a microplate reader (ELISA reader) and graphed.
As a result, as shown in FIG. 1, it was confirmed that the complex extract of Stauntonia chinensis and Corni fructus was not cytotoxic.
Experimental example 1 confirmation of Effect of inhibiting expression of Prostate Specific Antigen (PSA), Androgen Receptor (AR) and 5-alpha reductase 2(5 alpha-reductase 2) proteins in a Complex extract of Japanese stauntonvine and Cornus officinalis
In order to examine whether the compound extract of Japanese stauntonvine and dogwood is effective for the treatment of prostate diseases, the expression of androgen receptor, prostate specific antigen and 5-alpha reductase 2 protein was confirmed after treating prostate cancer cells with testosterone and the compound extract of Japanese stauntonvine and dogwood.
Specifically, LNCaP cells (ATCC company, USA) were plated in 6-well plates at 5X 104The cell/well concentration was divided, and the cells were cultured at 37 ℃ for 18 hours. Then, the cultured cells were treated with testosterone (1. mu.l) and treated with the Japanese stauntonvine extract prepared in example 1 at a concentration of 25. mu.g/ml or 50. mu.g/ml, the Corni fructus extract prepared in example 2 at a concentration of 50. mu.g/ml, or the Japanese stauntonvine and Corni fructus complex extract prepared in example 3 at a concentration of 50. mu.g/ml, and then cultured for 72 hours and recovered. Instead of the extract treatment, 1 μ M testosterone was used as a positive control group (BPH), and 10 μ M Finasteride (Finasteride) as a therapeutic agent for prostatic hyperplasia was used instead of the extract, and 1 μ M testosterone was used as a control group (Finasteride). Also, sabal palm (Saw Palmetto) as a therapeutic agent for prostatic hyperplasia, 100. mu.g/ml was used as a control group (sabal palm) by treating with 1. mu.M testosterone instead of the extract. The non-treated group was used as a negative Control group (Control).
The cells recovered after the culture were treated with RIPA lysis buffer (RIPA buffer) (50mM Tris-HCl, pH 8.0, 150mM sodium chloride (sodium chloride), 1% ethylphenylpolyethylene glycol (NP-40), 0.5% sodium deoxycholate (sodium deoxycholate), 0.1% sodium dodecyl sulfate (sodium dodecyl sulfate), and a mixture of protease inhibitors (cocktail)), and the proteins were separated by centrifugation at 12000rpm for 20 minutes. Quantification was performed by the Bicinchoninic acid (BCA) method.
10g of the quantified proteins were treated with sodium dodecyl sulfate polyacrylamide (SDS-PEGE) gel to perform electrophoresis, and then the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane. Thereafter, the polyvinylidene fluoride membrane was reacted in 5% skim milk (skimmilk) for about 1 hour to remove non-specifically bound proteins on the surface, and then reacted at a temperature of 4 ℃ for one day using an anti-Androgen Receptor (AR) antibody, an anti-Prostate Specific Antigen (PSA) antibody, an anti-5- α reductase 2(5 α -reductase 2) antibody, and an anti- β -actin (β -actin) antibody as primary antibodies. After that, after 1 hour of treatment at room temperature with the secondary antibody, the expression of the androgen receptor, prostate-specific antigen and antibody, and 5- α reductase 2 protein were confirmed and graphed using an ECL kit (Amersham, uk).
As a result, as shown in FIG. 2, it was confirmed that the inhibitory effect on the protein expression of androgen receptor and prostate specific antigen was significantly superior in the cell group treated with 25. mu.g/ml of the compound extract of Japanese stauntonvine and Corni fructus compared to the cell group treated with 25. mu.g/ml or 50. mu.g/ml of the extract of Japanese stauntonvine or Corni fructus alone. In addition, it was confirmed that the effect of inhibiting the expression of the protein of the androgen receptor and the prostate specific antigen was more excellent in the cell group treated with the compound extract of Japanese stauntonvine and dogwood in which the extract of Japanese stauntonvine and the extract of dogwood were mixed at a mixing ratio of 9: 1. Meanwhile, it was confirmed that the cell group treated with the compound extract of Japanese stauntonvine and dogwood has an excellent effect of inhibiting the expression of 5-alpha reductase 2 protein.
Examples of the preparation of the composition used in the present invention are shown below.
Preparation example 1 preparation of pharmaceutical preparation
1-1 preparation of powder
Powders were prepared by mixing 10mg of the complex extract of the present invention and 1g of lactose and filling into a gas-tight pad.
1-2 preparation of tablets
Tablets were prepared by mixing 0.1mg of the complex extract of the present invention, 100mg of corn starch, 100mg of lactose and 2mg of magnesium stearate, and tabletting according to a conventional tablet preparation method.
1-3 preparation of capsules
After mixing 0.1mg of the complex extract of the present invention, 100mg of corn starch, 100mg of lactose and 2mg of magnesium stearate, gelatin capsules were filled according to a common capsule preparation method to prepare capsules.
1-4 preparation of pills
After mixing 1mg of the complex extract of the present invention, 1.5g of lactose, 1g of glycerol, and 0.5g of xylitol, it was prepared in such a manner that 4g per pill was prepared according to a conventional method.
1-5 preparation of granules
After mixing 0.15mg of the complex extract of the present invention, 50mg of the soybean extract, 200mg of glucose and 600mg of starch, 100mg of 30% ethanol was added, and the mixture was dried at 60 ℃ to form granules, which were then filled in a hermetically sealed bag.
Preparation example 2 preparation of health food
A food containing the complex extract of the present invention as an active ingredient was prepared by the following method.
2-1 preparation of flour food
The compound extract of the present invention is added to flour in an amount of 0.5 to 5.0 parts by weight, and the mixture is used to prepare bread, cake, biscuit, cracker and pasta.
2-2 preparation of soups and gravies
The compound extract of the present invention is added in an amount of 0.1 to 5.0 parts by weight to a soup or a meat juice to prepare a meat-processed product, a pasta soup or a meat juice for health promotion.
2-3 preparation of ground beef
The ground beef for health promotion is prepared by adding 10 parts by weight of the composite extract of the present invention to the ground beef.
2-4 preparation of Dairy products
The composite extract of the present invention is added to milk in an amount of 5 to 10 parts by weight, and the milk is used to prepare various dairy products such as butter and ice cream.
2-5 preparation of Zen food
The product obtained by converting brown rice, barley, glutinous rice, and pearl barley into alpha-form and drying the alpha-form is baked by a known method, and then pulverized by a pulverizer to obtain a powder having a particle size of 60 mesh.
The product obtained by steaming black bean, black sesame and common perilla and drying by a known method is baked and then prepared into powder with the granularity of 60 meshes by a pulverizer.
The composite extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, dried using a spray or hot air dryer to obtain a dried product, and the dried product was pulverized into a particle size of 60 mesh using a pulverizer to obtain a dried powder.
The grains, the seeds and the compound extract are prepared by mixing the following components in proportion: cereals (30 parts by weight of brown rice, 15 parts by weight of coix seed and 20 parts by weight of barley), seeds (7 parts by weight of common perilla seed, 8 parts by weight of black bean and 7 parts by weight of black sesame), composite extract (3 parts by weight) of the invention, lucid ganoderma (0.5 part by weight) and rehmannia root (0.5 part by weight).
Preparation example 3 preparation of health drink
3-1 preparation of health beverage
The extract is prepared by uniformly blending a sub-material such as liquid fructose (0.5%), oligosaccharide (2%), sucrose (2%), salt (0.5%) and water (75%) with 0.5g of the composite extract of the present invention, subjecting the mixture to flash sterilization, and packaging the mixture in a small packaging container such as a glass bottle or a polyethylene terephthalate (PET) bottle.
Preparation method of 3-2 vegetable juice
Vegetable juice was prepared by adding 0.5g of the composite extract of the present invention to 1000ml of tomato juice or carrot juice.
3-3 preparation of fruit juice
Fruit juice was prepared by adding 0.1g of the complex extract of the present invention to 1000ml of apple juice or grape juice.
Industrial applicability
The present invention relates to a composition for preventing or treating prostate diseases comprising extracts of chaenomeles japonicas and cornus officinalis as active ingredients, and more particularly, to a composition for preventing or treating prostate diseases, which comprises a compound extract of chaenomeles japonicas and cornus officinalis as an active ingredient, has no cytotoxicity, and has an excellent inhibitory effect on the expression of androgen receptors, prostate-specific antigens and prostate-specific enzymes, and thus can be effectively used as an active ingredient of a composition for preventing or treating prostate diseases.
Claims (14)
1. A pharmaceutical composition for preventing or treating prostate diseases, characterized by comprising Japanese stauntonvine extract and dogwood extract as active ingredients.
2. The pharmaceutical composition for preventing or treating prostate disorders according to claim 1, wherein said extract is selected from the group consisting of water, C1To C2Or a mixed solvent thereof.
3. The pharmaceutical composition for preventing or treating prostate diseases according to claim 2, wherein said extract is extracted with one or more solvents selected from the group consisting of water, methanol, ethanol, and a mixed solvent thereof.
4. The pharmaceutical composition for preventing or treating prostate diseases according to claim 1, wherein said extract is an extract of at least one selected from the group consisting of flowers, branches, stems, leaves, fruits, aerial parts, rhizomes, and roots.
5. The pharmaceutical composition for preventing or treating prostate diseases according to claim 1, wherein said composition comprises the extract of chaenomeles speciosa and the extract of cornus officinalis in a weight ratio of 5: 5 to 9.5: 0.5.
6. The pharmaceutical composition for preventing or treating prostate diseases according to claim 1, wherein said composition comprises the extract of chaenomeles speciosa and the extract of cornus officinalis in a weight ratio of 6: 4 to 9.5: 0.5.
7. The pharmaceutical composition according to claim 1, wherein the prostate disease is selected from the group consisting of prostate cancer, prostatic hyperplasia and prostatitis.
8. A health food for preventing or improving prostate diseases, characterized by comprising Japanese stauntonvine extract and dogwood extract as active ingredients.
9. A food composition for preventing or improving prostate diseases, characterized by comprising Japanese stauntonvine extract and dogwood extract as active ingredients.
10. A method for preventing or ameliorating a prostate disease, comprising the step of administering a pharmaceutically effective amount of Japanese stauntonvine extract and Corni fructus extract to an individual.
11. A method for treating a prostate disease, comprising the step of administering a pharmaceutically effective amount of Japanese stauntonvine extract and Corni fructus extract to an individual.
12. Use of a Japanese stauntonvine extract and a dogwood extract is characterized in that the Japanese stauntonvine extract and the dogwood extract are used as a pharmaceutical composition for preventing or treating prostate diseases.
13. Use of a Japanese stauntonvine extract and a dogwood extract is characterized in that the Japanese stauntonvine extract and the dogwood extract are used as health food for preventing or improving prostate diseases.
14. Use of a Japanese stauntonvine extract and a dogwood extract is characterized in that the Japanese stauntonvine extract and the dogwood extract are used as a food composition for preventing or improving prostate diseases.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0101933 | 2018-08-29 | ||
| KR1020180101933A KR102167290B1 (en) | 2018-08-29 | 2018-08-29 | Composition for preventing or treating prostatic diseases comprising Stauntonia hexaphylla extract and Cornus officinalis as active ingredients |
| PCT/KR2019/009518 WO2020045838A1 (en) | 2018-08-29 | 2019-07-31 | Composition for prevention or treatment of prostate disease, containing extract from stauntonia hexaphylla and cornus officinalis as active ingredients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112638394A true CN112638394A (en) | 2021-04-09 |
Family
ID=69643001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980055052.XA Pending CN112638394A (en) | 2018-08-29 | 2019-07-31 | Composition for preventing or treating prostate disease comprising Japanese stauntonvine extract and dogwood extract as active ingredients |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR102167290B1 (en) |
| CN (1) | CN112638394A (en) |
| WO (1) | WO2020045838A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302717A (en) * | 2011-09-30 | 2012-01-04 | 姜新田 | Traditional Chinese medicine composition and medical pad for treating prostatic disease, and preparation method of medical pad |
| CN104173681A (en) * | 2014-09-15 | 2014-12-03 | 程惠华 | Traditional Chinese herbal medicine composition for treating castration-resistant prostate cancer |
| KR101652073B1 (en) * | 2015-10-12 | 2016-08-29 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Diseases Comprising Stauntonia Hexaphylla Extract |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101523586B1 (en) * | 2013-07-11 | 2015-05-29 | 상지대학교산학협력단 | Pharmaceutical composition for preventing or treating prostatic hyperplasia and preparation method thereof |
| KR101675930B1 (en) * | 2015-04-02 | 2016-11-14 | 유의순 | Anticancer composition comprising herbal extracts |
| KR101733477B1 (en) | 2015-06-04 | 2017-05-11 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Diseases Comprising Albizziae Cortex Extract |
| KR20170117339A (en) * | 2016-04-12 | 2017-10-23 | 주식회사 케미메디 | Medical composition for preventing or treating chronic bacterial prostatitis |
| KR101895548B1 (en) * | 2017-01-16 | 2018-09-06 | 대구한의대학교산학협력단 | Pharmaceutical composition comprising Korean medicinal herbs for preventing hair loss, melanizing of hair, enhancing hair growth, treating benign prostate hyperplasia and manufacturing method thereof |
-
2018
- 2018-08-29 KR KR1020180101933A patent/KR102167290B1/en active IP Right Grant
-
2019
- 2019-07-31 CN CN201980055052.XA patent/CN112638394A/en active Pending
- 2019-07-31 WO PCT/KR2019/009518 patent/WO2020045838A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302717A (en) * | 2011-09-30 | 2012-01-04 | 姜新田 | Traditional Chinese medicine composition and medical pad for treating prostatic disease, and preparation method of medical pad |
| CN104173681A (en) * | 2014-09-15 | 2014-12-03 | 程惠华 | Traditional Chinese herbal medicine composition for treating castration-resistant prostate cancer |
| KR101652073B1 (en) * | 2015-10-12 | 2016-08-29 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Diseases Comprising Stauntonia Hexaphylla Extract |
Non-Patent Citations (1)
| Title |
|---|
| 李范洙: "《Effects of corni fructus extract on Testosterone-induced Benign Prostatic Hyperplasia in Rats》", 《KYONGHUI UNIVERSITY MASTER"S DEGREE PAPER》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200025093A (en) | 2020-03-10 |
| WO2020045838A1 (en) | 2020-03-05 |
| KR102167290B1 (en) | 2020-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111544461A (en) | Panax plant extract produced by microwave irradiation, method for producing the same, and composition containing the same | |
| KR101883065B1 (en) | Composition containing natural extract for preventing or treating benign prostatic hyperplasia | |
| KR20160011174A (en) | Food composition comprising cynanchum wilfordii potentiating testosterone excretion as an active ingredient | |
| KR101552813B1 (en) | Compositions for preventing or treating benign prostatic hyperplasia comprising extracts of Quisqualis indica | |
| KR101726757B1 (en) | Composition for prevention and treatment of climacteric disorder comprising extracts of Dendropanax morbifera as an active ingredient | |
| EP3144005A1 (en) | Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof | |
| KR102081156B1 (en) | Composition comprising corni fructus extracts for preventing or treating benign prostatic hypertrophy | |
| KR102080410B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts | |
| CN100367878C (en) | Bitter gourd health food and its preparation method | |
| KR101828167B1 (en) | Composition for anti-obesity comprising the extract of aronia and method for preparing thereof | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| KR101165719B1 (en) | Composition for the prevention and treatment of benign prostatic hyperplasia comprising extract of Melandrium Firmum | |
| KR102167290B1 (en) | Composition for preventing or treating prostatic diseases comprising Stauntonia hexaphylla extract and Cornus officinalis as active ingredients | |
| KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
| KR101420270B1 (en) | Composition comprising reacted mixture of red ginseng extract and persimmon vinegar for preventing or treating benign prostatic hyperplasia | |
| KR20230017389A (en) | Composition for preventing or treating chronic prostatitis and lower urinary tract symptoms | |
| KR20050014615A (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
| KR101026523B1 (en) | Pharmaceutical composition and food additives containing extract of black onion for prevention and treatment of overweight or obesity | |
| KR20230076447A (en) | Pharmaceutical composition for preventing or treating benign prostatic hyperplasia comprising ethanol extract of Cornus officinalis | |
| KR20160011175A (en) | Food composition comprising cynanchum wilfordii potentiating testosterone excretion as an active ingredient | |
| CN106138591A (en) | Containing Fructus Lycii and the maca composition of Qi-tonifying drug | |
| KR101157508B1 (en) | Composition for prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera root | |
| KR102508704B1 (en) | Complex formulation for preventing hair loss with a core-shell structure and health functional food having the same | |
| KR102158661B1 (en) | Composition for preventing, ameliorating and treating inflammatory diseases comprising extract of undried immature astrigent persimmon of miyrangbansi as effective component | |
| KR20110096194A (en) | Composition for the prevention and treatment metabolic disorders comprising extracts of nelumbo nucifera leaf and taurine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210409 |
|
| RJ01 | Rejection of invention patent application after publication |